DPL
DIPNA PHARMACHEM financials
- Market cap
- ₹20 Cr
Quarterly results
Q4 FY26: revenue down 97.7% against the same quarter last year.
| Line item | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 74 | 74 | 90 | 91 | 16 −78% | 74 +0% | 54 −41% | 2 −98% |
| EBITDA | 2 | 2 | 2 | 1 | 1 −36% | 3 +50% | 2 −18% | 0 −54% |
| Net profit | 1 | 1 | 0 | 0 | 1 −50% | 1 +0% | 1 | 0 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −78.8% 1Y
1Y: ₹21.94 on 9 Sept 2025 → ₹4.65. High ₹24.1 (13 Oct 2025), low ₹4.17 (4 Aug 2026).
Balance sheet
| Year ending | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹12 Cr | ₹24 Cr | ₹24 Cr |
| Reserves | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹12 Cr | ₹13 Cr | ₹35 Cr |
| Borrowings | ₹10 Cr | ₹12 Cr | ₹10 Cr | ₹16 Cr | ₹19 Cr | ₹14 Cr |
| Other liabilities | ₹8 Cr | ₹12 Cr | ₹24 Cr | ₹37 Cr | ₹76 Cr | ₹105 Cr |
| Total liabilities | ₹18 Cr | ₹25 Cr | ₹36 Cr | ₹78 Cr | ₹133 Cr | ₹177 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹18 Cr | ₹25 Cr | ₹36 Cr | ₹78 Cr | ₹133 Cr | ₹177 Cr |
| Total assets | ₹18 Cr | ₹25 Cr | ₹36 Cr | ₹78 Cr | ₹133 Cr | ₹177 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Mar 2025, promoters trimmed −0.85 pp while the public added +0.85 pp. The shareholder count shrank 10% to 1,788.
- Promoters
- 9.1%
- Public
- 90.9%
Since Mar 2025
- Promoters −0.85 pp
- Public +0.85 pp
How it drifted, 10 quarters
Over this window promoters fell from 66.6% to 9.1% — −57.4 pp.
Ownership split by quarter, oldest first. Sep '22: Promoters 66.6%, Public 33.5%.Mar '23: Promoters 66.6%, Public 33.4%.Sep '23: Promoters 57.2%, Public 42.8%.Mar '24: Promoters 10.0%, Public 90.0%.Sep '24: Promoters 10.0%, Public 90.0%.Mar '25: Promoters 10.0%, Public 90.0%.Sep '25: Promoters 10.0%, Public 90.0%.Nov '25: Promoters 9.1%, Public 90.9%.Mar '26: Promoters 9.1%, Public 90.9%.Jun '26: Promoters 9.1%, Public 90.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Falguni Yogendra Trivedi newly disclosed 1.14% held
- Kaavya Agrawal newly disclosed 1.04% held
The same filing shows 3 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of DIPNA PHARMACHEM LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Keyur Dipakkumar Shah | 9.12% | unchanged |
| Kajal Ashok Jain | 4.28% | unchanged |
| Ashok Dilipkumar Jain | 4.26% | unchanged |
| Siddharth Poddar | 4.11% | unchanged |
| Namita Hemant Jain | 3.59% | −0.62 pp |
| Teena Kirti Jain | 3.26% | −0.49 pp |
| Vibha R Tripathi | 2.62% | unchanged |
| Sanjay Nirmal Jain Huf | 2.43% | −0.07 pp |
| Neerita Sanjay jain | 2.19% | unchanged |
| Maheshbhai Jivanbhai Ramani | 2.19% | unchanged |
| Girish Ganesh Sathe | 1.94% | unchanged |
| Sunita Santosh Goenka | 1.83% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse DIPNA PHARMACHEM LIMITED
Guides on how to read this kind of business and the numbers that matter.